Citicoline data

Preliminary results of a Phase III trial of citicholine showed a statistically significant improvement in the recovery of patients with ischemic stroke, compared with those receiving placebo.

Compared to placebo at 12 weeks after stroke, patients who received the low dose (500 mg/day) of citicoline were 1.6 times as likely to show minimal or no disability as measured by the primary outcome measure, the Barthel index. They were more than twice as likely to manifest minimal or no disability, as measured by the NIH Stroke Scale. Both indices are standard measurements of stroke symptoms and functional abilities related to daily living. ...